All In Biotech

Drug Trial Radar · NCT04930536

Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma

A Prospective, Multi-centre, Phase IV Clinical Trial to Assess the Safety and Efficacy of Acalabrutinib Capsules in Indian Adult Patients With Chronic Lymphocytic Leukaemia and Relapsed and Refractory Mantle Cell Lymphoma.

Last checked: Nov 20, 2026Latest source record: Nov 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

103

Actual

Start

Jul 14, 2021

Primary completion

May 2, 2023

Study completion May 2, 2023

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jun 18, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is plan to assess the safety and efficacy of Acalabrutinib in Indian patients with chronic lymphocytic leukaemia (CLL) and relapsed and refractory mantle cell lymphoma (MCL)

Conditions

  • Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma

Interventions

  • Acalabrutinib capsuleDrug

    The recommended dose of Acalabrutinib is 100 mg given per oral (PO) twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events of Special Interest (AESI) Including Arrhythmias (Atrial Fibrillation), Anaemia, Hypertension, Bleeding, InfectionsTime frame: Throughout study completion, approximately 198 days (from the Screening Phase [Day 0], Treatment Phase [Days 1-170], and until the Follow-up Phase [28 days after Day 170])
  2. Second Primary MalignanciesTime frame: Throughout study completion, approximately 198 days (from the Screening Phase [Day 0], Treatment Phase [Days 1-170], and until the Follow-up Phase [28 days after Day 170])

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Ahmedabad, India

  • Research Site

    Bangalore, India

  • Research Site

    Bangalore, India

  • Research Site

    Bengaluru, India

  • Research Site

    Chandigarh, India

  • Research Site

    Gurugram, India

  • Research Site

    Guwahati, India

  • Research Site

    Hyderabad, India

  • Research Site

    Hyderabad, India

  • Research Site

    Kochi, India

  • Research Site

    Kolkata, India

  • Research Site

    Ludhiana, India

  • Research Site

    Mumbai, India

  • Research Site

    Mumbai, India

  • Research Site

    New Delhi, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.